Central European Journal of Medicine

, Volume 8, Issue 3, pp 322–327 | Cite as

Malignancies after kidney transplantation: 3 clinical case reports

  • Eglė Dalinkevičienė
  • Vytautas Kuzminskis
  • Laura Kairevičė
  • Rasa Jančiauskienė
  • Daimantas Milonas
  • Mindaugas Jievaltas
  • Birutė Sribikienė
  • Inga-Arūnė Bumblytė
Case Report


Post-transplant malignancies present an aggressive course and are a significant cause of morbidity and mortality. Tumours of viral ethiology have the greatest risk in renal transplant recipients. Oncogenic effect of immunosuppressive therapy is another major risk factor of post-transplant malignancy. We report cases of three different types of malignancies developed after kidney transplantation: non-Hodgkin’s lymphoma, Kaposi’s sarcoma and germ cell testicular cancer (nonseminoma).


Kidney transplantation Malignancy Non-Hodgkin’s lymphoma Kaposi’s sarcoma Germ cell testicular cancer (nonseminoma) 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Sheil AG, Disney APS, Mathew TH, et al. De novo malignancy emerges as a major causes of morbidity and late failure in renal transplantation. Transplant Proc 1993;25:1383PubMedGoogle Scholar
  2. [2]
    Peto J. Cancer epidemiology in the last century and the next decade. Nature 2001;411:390–395PubMedCrossRefGoogle Scholar
  3. [3]
    Birkeland SA, Lokkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet 2000;355:1886–1887PubMedCrossRefGoogle Scholar
  4. [4]
    Zeier M, Hartschuh W, Wiesel M, Lehnert T, Ritz E. Malignancy after renal transplantation. Am J Kidney Dis 2002;39:E5PubMedCrossRefGoogle Scholar
  5. [5]
    Wimmer CD, Rentsch M, Crispin A, et al. The janus face of immunosuppression — de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int. 2007;71:1271–1278PubMedCrossRefGoogle Scholar
  6. [6]
    Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am. J. Transplant. 2004;4:905–913PubMedCrossRefGoogle Scholar
  7. [7]
    Morath C, Mueller M, Goldschmidt H et al. Malignancy in renal transplantation. J Am Soc Nephrol 2004;15:1582–1588PubMedCrossRefGoogle Scholar
  8. [8]
    Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for endstage renal disease: an international collaborative study. Lancet 1999;354:93–99PubMedCrossRefGoogle Scholar
  9. [9]
    Briggs JD. Causes of death after renal transplantation. Nephrol. Dial. Transplant. 2001;16:1545–154PubMedCrossRefGoogle Scholar
  10. [10]
    Yang TC, Shu KH, Cheng CH, Wu MJ, Lian JD. Malignancy following renal transplantation. Zhonghua Yi Xue Za Zhi (Taipei) 1998;61:281–288Google Scholar
  11. [11]
    Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002;73:1923–1928PubMedCrossRefGoogle Scholar
  12. [12]
    Collins AJ, et al. Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2003;42(5):S1–S230Google Scholar
  13. [13]
    Miao Y, Everly JJ, Gross TG, Tevar AD et al. De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation 2009;87:1347–1359PubMedCrossRefGoogle Scholar
  14. [14]
    Kauffman HM, Cherikh WS, McBride MA et al. Posttransplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int 2006; 19:607–620PubMedCrossRefGoogle Scholar
  15. [15]
    Caillard S, Dharnidharka V, Agodoa L et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80:1233–1243PubMedCrossRefGoogle Scholar
  16. [16]
    Liebowitz, D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med. 1998; 338:1413–1421PubMedCrossRefGoogle Scholar
  17. [17]
    Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4:222–230PubMedCrossRefGoogle Scholar
  18. [18]
    Dantal J, Hourmant M, Cantorovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomized comparison of two cyclosporin regimens. Lancet 1998;351:623–628PubMedCrossRefGoogle Scholar
  19. [19]
    Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant. 2007;7:2619–2625PubMedCrossRefGoogle Scholar
  20. [20]
    Schmidtko J, Wang R, Wu CL, et al. Posttransplant lymphoproliferative disorder associated with an Epstein-Barr-related virus in cynomolgus monkeys. Transplantation 2002;73:1431–1439PubMedCrossRefGoogle Scholar
  21. [21]
    Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342:1514–1516PubMedCrossRefGoogle Scholar
  22. [22]
    Campistol JM, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006;1:581–589CrossRefGoogle Scholar
  23. [23]
    Kahan BD, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005;80:749–758PubMedCrossRefGoogle Scholar
  24. [24]
    Chapman JR, Capistol JM. Malignancy in renal transplantation: opportunities with proliferation signal inhibitors. Nephrol Dial Transplant 2007;22 (l):i1–i3CrossRefGoogle Scholar
  25. [25]
    Gurk-Turner C, Manitpisitkul W, Cooper M. A comprehensive review of everolimus clinical reports: a new Mammalian target of rapamycin inhibitor. Transplantation. 2012;94(7):659–68PubMedCrossRefGoogle Scholar
  26. [26]
    Kasiske BL, Kukla A, Thomas D, et al. Lymphoproliferative Disorders After Adult Kidney Transplant: Epidemiology and Comparison of Registry Report With Claims-Based Diagnoses. Am J Kidney Dis 2011;58(6):971–980PubMedCrossRefGoogle Scholar
  27. [27]
    Gotti E, Remuzzi G: Post-transplant Kaposi’s sarcoma. J Am Soc Nephrol 1997;8:130–137PubMedGoogle Scholar
  28. [28]
    Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi’s sarcoma. Transplantation 2004;77:760–762PubMedCrossRefGoogle Scholar
  29. [29]
    Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317–1323PubMedCrossRefGoogle Scholar
  30. [30]
    Shepherd FA, Maher E, Cardella C, et al. Treatment of Kaposi’s sarcoma after solid organ transplantation. J Clin Oncol 1997;15:2371–2377PubMedGoogle Scholar
  31. [31]
    Brambilla L, Labianca R, Boneschi V, et al. Mediterranean Kaposi’s sarcoma in the elderly: a randomized study of oral etoposide versus vinblastine. Cancer 1994;74:2873–2878PubMedCrossRefGoogle Scholar
  32. [32]
    Olay Dahl, Geirfinn Vagstad, Bjarne Iversen. Cisplatin-based chemotherapy in a renal transplant recipient with metastatic germ cell testicular cancer. Acta Oncologica 1996; 35:759–761PubMedCrossRefGoogle Scholar
  33. [33]
    Dean C, Bloomfield D, Holt S. The challenge of germ cell tumour therapy in dialysis and transplantation. Nephrol Dial Transplant. 2005;20(12):2867–2868PubMedCrossRefGoogle Scholar
  34. [34]
    Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol. 2000;11:S1–86PubMedGoogle Scholar
  35. [35]
    European Best Practice Guidelines. Nephrol Dial Transplant 2002;17(4):37Google Scholar
  36. [36]
    Penn I. Transmission of cancer from organ donor. Nefrologia 1995;15(3):205–213Google Scholar
  37. [37]
    Kauffman HM, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation. 2000;70(12):1747–1751PubMedCrossRefGoogle Scholar
  38. [38]
    Garrido G, Matesanz R. The Spanish National Transplant Organization (ONT) tumor registry. Transplantation 2008;85(8):S61–63PubMedCrossRefGoogle Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Eglė Dalinkevičienė
    • 1
  • Vytautas Kuzminskis
    • 1
  • Laura Kairevičė
    • 2
  • Rasa Jančiauskienė
    • 2
  • Daimantas Milonas
    • 3
  • Mindaugas Jievaltas
    • 3
  • Birutė Sribikienė
    • 1
  • Inga-Arūnė Bumblytė
    • 1
  1. 1.Department of Nephrology, Medical AcademyLithuanian University of Health SciencesKaunasLithuania
  2. 2.Department of Onco-haematology, Medical AcademyLithuanian University of Health SciencesKaunasLithuania
  3. 3.Department of Urology, Medical AcademyLithuanian University of Health SciencesKaunasLithuania

Personalised recommendations